Fenwick & West LLP represented Halozyme Therapeutics, a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care, in a $515 million licensing agreement with Pfizer that will allow for the collaboration, development and commercialization of products combining proprietary Pfizer biologics with Halozyme's Enhanze™ technology, a proprietary drug delivery platform based on the Company's patented recombinant human hyaluronidase enzyme (rHuPH20). Under terms of this agreement, Pfizer has been granted a worldwide license to develop and commercialize products combining rHuPH20 with Pfizer proprietary biologics directed to up to six targets. Halozyme will receive an initial payment of $8 million and is eligible to receive additional payments upon Pfizer's achievement of specified development, regulatory and sales-based milestones, totaling up to $507 million.
The Fenwick transaction team was led by intellectual property partner Jake Handy and included intellectual property associate Claire O’Callaghan.